Bloomios, Inc. (BLMS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Bloomios, Inc. (BLMS) trades at $0.00 with AI Score 49/100 (Grade C). Bloomios, Inc. manufactures and distributes cannabidiol (CBD) products, including edibles, tinctures, and topicals, through wholesale and retail channels. Market cap: $6,447, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for BLMS: BLMS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BLMS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BLMS: the 1 perspectives are evenly split.
How is this calculated? →Bloomios, Inc. (BLMS) Healthcare & Pipeline Overview
Bloomios, Inc. focuses on manufacturing and distributing a range of cannabidiol (CBD) products, including edibles, tinctures, and topicals. Operating within the specialty and generic drug manufacturing sector, the company targets both wholesale and retail distribution channels for its hemp-derived supplements and cosmetic products.
What Is the Investment Thesis for BLMS?
Bloomios, Inc. operates in the high-growth CBD market, but its financial performance and OTC listing present significant risks. With a negative profit margin of -226.7% and a market capitalization of 6K as of March 2026, the company's financial stability is uncertain. The company's gross margin stands at 36.7%. Key growth catalysts include expanding distribution channels and introducing new product lines. However, investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and regulatory uncertainty. The company's ability to achieve profitability and navigate the competitive landscape will be critical to its long-term success.
Based on FMP financials and quantitative analysis
BLMS Key Highlights
- Market Cap of 6K indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -226.7% highlights significant operational challenges and the need for improved cost management.
- Gross Margin of 36.7% suggests potential for profitability if operating expenses are better controlled.
- Beta of -0.53 indicates the stock is less volatile than the market, but this may also reflect limited trading activity.
Who Are BLMS's Competitors?
BLMS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BLMS's Key Strengths?
- Diverse product range across multiple CBD categories.
- Established wholesale and retail distribution channels.
- Focus on hemp-derived supplements and cosmetic products.
- Experienced management team in the CBD industry.
What Are BLMS's Weaknesses?
- Negative profit margin and limited financial resources.
- Small market capitalization and OTC listing.
- Limited brand recognition compared to larger competitors.
- Dependence on the evolving regulatory landscape for CBD products.
What Could Drive BLMS Stock Higher?
- Potential regulatory changes in the CBD market could create new opportunities or challenges for Bloomios.
- Expansion of distribution channels through strategic partnerships with retailers.
- Introduction of new and innovative CBD products to meet evolving consumer demand.
- Increased consumer awareness and acceptance of CBD products.
- Development of white label and private label opportunities to diversify revenue streams.
What Are the Key Risks for BLMS?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Increased competition from larger companies entering the CBD market.
- Negative publicity or health concerns related to CBD products.
- Fluctuations in the price of hemp and other raw materials.
- Regulatory uncertainty and potential restrictions on CBD products.
- Limited financial resources and negative profit margin.
What Are the Growth Opportunities for BLMS?
- Expansion of Product Line: Bloomios can drive growth by introducing new and innovative CBD products, such as specialized formulations targeting specific health conditions or novel delivery methods. The market for CBD-infused beverages and edibles is projected to reach $2.8 billion by 2028, presenting a significant opportunity for Bloomios to capture market share through product innovation and effective marketing.
- Strategic Partnerships: Forming strategic partnerships with established retailers and distributors can significantly expand Bloomios' market reach and brand visibility. Collaborating with national pharmacy chains or health food stores could provide access to a broader customer base and enhance the company's credibility. The timeline for establishing such partnerships is estimated at 12-18 months, with potential revenue impact within the following year.
- E-commerce Expansion: Investing in a robust e-commerce platform and digital marketing strategies can enable Bloomios to reach a global audience and drive online sales. The online CBD market is experiencing rapid growth, with projections estimating a market size of $16 billion by 2027. By optimizing its online presence and offering a seamless customer experience, Bloomios can capitalize on this trend and increase its direct-to-consumer sales.
- White Label and Private Label Opportunities: Bloomios can leverage its manufacturing capabilities to offer white label and private label CBD products to other companies. This can provide a stable revenue stream and diversify the company's customer base. The market for white label CBD products is growing as more businesses seek to enter the CBD market without investing in their own manufacturing infrastructure. Bloomios can target small to medium-sized businesses in the health and wellness sector.
- International Expansion: Exploring international markets, particularly in Europe and Asia, can unlock significant growth opportunities for Bloomios. The European CBD market is projected to reach $1.5 billion by 2025, while the Asian market is also showing increasing interest in CBD products. However, international expansion requires careful consideration of regulatory requirements and cultural differences. Bloomios can start by targeting countries with more favorable CBD regulations and establishing partnerships with local distributors.
What Opportunities Does BLMS Have?
- Expansion into new geographic markets.
- Development of innovative CBD formulations and delivery methods.
- Strategic partnerships with established retailers and distributors.
- Increased consumer awareness and acceptance of CBD products.
What Threats Does BLMS Face?
- Intense competition from other CBD manufacturers and distributors.
- Changing regulatory requirements and potential restrictions on CBD products.
- Fluctuations in the price of hemp and other raw materials.
- Negative publicity or health concerns related to CBD products.
What Are BLMS's Competitive Advantages?
- Product diversification across multiple CBD product categories.
- Established wholesale and retail distribution channels.
- Proprietary formulations and manufacturing processes.
- Brand recognition and customer loyalty in the CBD market.
What Does BLMS Do?
Bloomios, Inc., formerly known as XLR Medical Corp., rebranded in April 2021 to concentrate on the cannabidiol (CBD) market. Incorporated in 2001 and headquartered in Santa Barbara, California, the company manufactures, markets, and distributes a diverse portfolio of CBD products. These include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. Bloomios distributes its hemp-derived supplements and cosmetic products through both wholesale partnerships and direct retail channels, aiming to capitalize on the growing consumer interest in CBD-based health and wellness solutions. The company's strategy involves expanding its product line and distribution network to reach a broader customer base in the competitive CBD market. Bloomios faces the challenges of navigating regulatory complexities and differentiating itself in a crowded field of CBD product manufacturers and distributors. The company's success depends on effective marketing, product innovation, and adherence to quality standards to build consumer trust and brand loyalty.
What Products and Services Does BLMS Offer?
- Manufactures cannabidiol (CBD) products.
- Markets CBD products through various channels.
- Distributes CBD products to wholesale and retail customers.
- Offers edibles, tinctures, oils, salves, capsules, balms, lotions, creams, and beverages.
- Provides CBD products for both human and pet consumption.
- Sells hemp-derived supplements and cosmetic products.
How Does BLMS Make Money?
- Manufacturing and selling CBD products.
- Generating revenue through wholesale distribution to retailers.
- Generating revenue through direct-to-consumer retail sales.
- Offering a diverse range of CBD product categories to cater to different consumer preferences.
What Industry Does BLMS Operate In?
Bloomios, Inc. operates within the rapidly expanding CBD market, which has seen significant growth due to increasing consumer acceptance of CBD products for various health and wellness applications. The market is characterized by intense competition, with numerous companies offering similar products. Key trends include the development of innovative CBD formulations, the expansion of distribution channels, and increasing regulatory scrutiny. Bloomios competes with other CBD manufacturers and distributors, including AIDA, ASFX, CENBF, MJNE, and SAGD, all of which are navigating the evolving regulatory landscape and striving to establish brand recognition.
Who Are BLMS's Key Customers?
- Retail consumers seeking CBD products for health and wellness.
- Wholesale distributors and retailers selling CBD products.
- Pet owners seeking CBD products for their pets.
- Customers interested in various forms of CBD consumption (e.g., edibles, topicals, tinctures).
Company Profile
Bloomios, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Santa Barbara, US. The company is led by CEO Michael Hill. BLMS has traded publicly since 2003.
F-Score 2/9Financial Health
Bloomios, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on assets is -53.0%, showing how much profit it generates from its asset base. A current ratio of 0.09 means current liabilities exceed short-term assets, a liquidity point worth watching.
BLMS Valuation & Market Position
With a 6K market cap, Bloomios, Inc. sits in the micro-cap segment of the market. Relative to its peer group, BLMS's quantitative score of 49/100 is below the peer average of 66/100.
BLMS Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Bloomios' growth trajectory, which can signal potential upside.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative product lines and market positioning.
- Increased social media buzz indicates growing awareness and interest in Bloomios, potentially attracting new investors.
- Recent partnerships or collaborations may enhance brand visibility and market reach, fostering optimism among stakeholders.
Bear Case
- Concerns about the overall market volatility may overshadow Bloomios' potential, leading to cautious sentiment among investors.
- Some community members express skepticism regarding the sustainability of recent growth, questioning long-term profitability.
- Negative news or regulatory challenges in the industry could dampen investor enthusiasm and create uncertainty around Bloomios' future.
- Insider selling activity in the past has raised red flags for some, leading to a bearish outlook among certain segments of the trading community.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
BLMS Latest News
No recent news available for BLMS.
BLMS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BLMS.
Price Targets
Wall Street price target analysis for BLMS.
BLMS MoonshotScore
What does this score mean?
The MoonshotScore rates BLMS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Michael Hill
CEO
Michael Hill serves as the CEO of Bloomios, Inc., managing a small team of three employees. Information regarding his detailed career history, education, and previous roles is not available. His leadership is focused on guiding Bloomios in the competitive CBD market, navigating regulatory challenges, and driving growth through product innovation and distribution expansion.
Track Record: Due to limited information on Michael Hill's prior experience and specific achievements at Bloomios, it is difficult to assess his track record. His success will be measured by the company's ability to achieve profitability, expand its market share, and navigate the evolving regulatory landscape for CBD products.
BLMS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Bloomios, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial disclosures, increasing the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to low trading volume on the OTC market.
- Lack of transparency due to potentially limited financial disclosures.
- Higher price volatility compared to stocks listed on major exchanges.
- Potential for pump-and-dump schemes or other fraudulent activities.
- Regulatory uncertainty surrounding CBD products and the company's operations.
- Verify the company's financial statements and SEC filings (if available).
- Research the background and experience of the company's management team.
- Assess the company's competitive position in the CBD market.
- Evaluate the company's compliance with relevant regulations.
- Monitor news and press releases for any red flags or potential risks.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- The company has been in operation since 2001.
- Bloomios has a diverse product range across multiple CBD categories.
- The company has established wholesale and retail distribution channels.
- Bloomios rebranded in 2021 to focus on the CBD market, indicating a strategic shift.
- The company's headquarters are located in Santa Barbara, California.
BLMS Healthcare Stock FAQ
What does Bloomios, Inc. do?
Bloomios, Inc. is a manufacturer and distributor of cannabidiol (CBD) products, catering to both human and pet consumption. The company offers a diverse range of CBD products, including edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. Bloomios distributes these hemp-derived supplements and cosmetic products through wholesale and retail channels, aiming to capitalize on the growing demand for CBD-based health and wellness solutions. The company's business model focuses on product innovation, effective marketing, and strategic distribution partnerships to reach a broad customer base.
What do analysts say about BLMS stock?
As of March 2026, there is no readily available analyst coverage for Bloomios, Inc. (BLMS) due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio and profit margin, indicate financial challenges. Potential investors should conduct thorough due diligence and consider the risks associated with OTC-listed companies before making any investment decisions. The company's growth prospects depend on its ability to improve profitability, expand its market share, and navigate the evolving regulatory landscape for CBD products.
What are the main risks for BLMS?
Bloomios, Inc. faces several key risks, including intense competition in the CBD market, regulatory uncertainty surrounding CBD products, and fluctuations in the price of hemp and other raw materials. The company's negative profit margin and limited financial resources also pose significant challenges. As an OTC-listed company, Bloomios is subject to limited liquidity and higher price volatility. Investors should carefully consider these risks before investing in BLMS.
What revenue streams does Bloomios, Inc. have in healthcare?
Bloomios, Inc. generates revenue primarily through the sale of its cannabidiol (CBD) products. These revenue streams are derived from both wholesale and retail distribution channels. The company's product line includes edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats, all of which contribute to the overall revenue. Bloomios focuses on marketing these products as hemp-derived supplements and cosmetic products to appeal to health-conscious consumers. The company's success depends on its ability to effectively market and distribute these products while navigating the evolving regulatory landscape for CBD in the healthcare sector.
How does Bloomios, Inc. navigate regulatory approval processes?
As a manufacturer and distributor of cannabidiol (CBD) products, Bloomios, Inc. operates in a complex and evolving regulatory environment. The company must comply with various federal, state, and local regulations governing the production, labeling, and sale of CBD products. While CBD products derived from hemp are generally legal under federal law, specific regulations vary by state. Bloomios must stay informed about these changing regulations and ensure its products meet all applicable requirements. The company's strategy involves working closely with legal counsel and industry experts to navigate the regulatory landscape and maintain compliance. Bloomios also monitors pending legislation and advocates for reasonable regulations that support the growth of the CBD industry.
What are the key factors to evaluate for BLMS?
Bloomios, Inc. (BLMS) holds an AI score of 49/100 (low). Not financial advice.
How frequently does BLMS data refresh on this page?
BLMS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BLMS's recent stock price performance?
Bloomios, Inc. (BLMS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product range across multiple CBD categories. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO background and track record.
- Financial data based on available information and may not be comprehensive.
- OTC market investments carry higher risk than exchange-listed stocks.